ESSA Pharma (NASDAQ: EPIX) is one of 481 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare ESSA Pharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings.
This table compares ESSA Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ESSA Pharma Competitors||-3,117.69%||-153.03%||-26.89%|
This is a breakdown of current ratings and target prices for ESSA Pharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ESSA Pharma Competitors||2759||8405||21179||565||2.59|
ESSA Pharma presently has a consensus target price of $0.70, indicating a potential upside of 279.20%. As a group, “Pharmaceutical preparations” companies have a potential upside of 50.08%. Given ESSA Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe ESSA Pharma is more favorable than its peers.
Institutional & Insider Ownership
6.0% of ESSA Pharma shares are held by institutional investors. Comparatively, 47.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.3% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
ESSA Pharma has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, ESSA Pharma’s peers have a beta of 1.08, suggesting that their average stock price is 8% more volatile than the S&P 500.
Valuation and Earnings
This table compares ESSA Pharma and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ESSA Pharma||N/A||-$4.72 million||-0.46|
|ESSA Pharma Competitors||$2.04 billion||$133.73 million||-3.24|
ESSA Pharma’s peers have higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
ESSA Pharma beats its peers on 7 of the 13 factors compared.
ESSA Pharma Company Profile
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.